Liposome Irinotecan: Clinical Trials

2 completed, 2 not yet recruiting. 3 Phase 2, 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 2, Not yet recruiting 1
Phase 4	1	Not yet recruiting 1

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Liposome Irinotecan, Platinum, Anlotinib - Small Cell Lung Cancer	Phase 2	Not yet recruiting	China Medical University, China	31	2026-01-25	2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Liposome Irinotecan, Platinum, Tislelizumab - Small Cell Lung Cancer	Phase 4	Not yet recruiting	China Medical University, China	31	2025-04-30	2025-04-30
Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer PEP02 - Pancreatic Neoplasms	Phase 2	Completed	PharmaEngine	41	2009-01-01	2019-09-06
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma PEP02, irinotecan, docetaxel - Stomach Neoplasms, Esophageal Neoplasms	Phase 2	Completed	PharmaEngine	135	2007-11-01	2012-03-02

Taiwan (2) · Bosnia and Herzegovina (1) · China (1) · Croatia (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)